Article ; Online: SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.
2022 Volume 12, Issue 1, Page(s) 3351
Abstract: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic ... ...
Abstract | Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8-99.9] sensitive and 88.9% [95% CI 51.8-99.7] specific at predicting the presence of NAbs (PRNT |
---|---|
MeSH term(s) | Aged ; Antibodies, Viral/immunology ; COVID-19/immunology ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Immunoglobulin G/immunology ; Immunoglobulin M/immunology ; Male ; Middle Aged ; Neutralization Tests ; SARS-CoV-2/immunology ; Spike Glycoprotein, Coronavirus/immunology |
Chemical Substances | Antibodies, Viral ; Immunoglobulin G ; Immunoglobulin M ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 |
Language | English |
Publishing date | 2022-03-01 |
Publishing country | England |
Document type | Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't |
ZDB-ID | 2615211-3 |
ISSN | 2045-2322 ; 2045-2322 |
ISSN (online) | 2045-2322 |
ISSN | 2045-2322 |
DOI | 10.1038/s41598-022-07263-8 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.